Abstracts tagged "pain"

Abstract Number: 0503 • ACR Convergence 2025
Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Andrey E. Karateev¹, Sofia Kuzkina², Alina Egorova³ and Elena Y. Polishchuk¹, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³R-Pharm JSC, Moscow, Russia
Background/Purpose: Pain is one of the most debilitating symptoms of rheumatoid arthritis (RA) and a major contributor to reduced quality of life. Persistent joint pain…
Abstract Number: 0292 • ACR Convergence 2025
Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies
Haley Zimmerman¹, Ethan Ritz², Kristin Wipfler³, Kaleb Michaud⁴ and Didem Saygin¹, ¹Rush University Medical Center, Chicago, IL, ²Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Idiopathic inflammatory myopathies (IIM) have historically been considered a disease of painless weakness. However, recent studies indicate that most patients with IIM experience pain…
Abstract Number: 2327 • ACR Convergence 2025
Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing
Rebecca Haberman¹, Kyra Chen², Adamary Felipe³, Stephanie Eichman³, Uma Scher⁴ and Jose Scher⁵, ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, ³NYU Grossman School of Medicine, New York, ⁴NYU School of Medicine, Scarsdale, NY, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Targeted synthetic and biologic DMARDs have transformed psoriatic arthritis (PsA) treatment. Still, a substantial subset of patients reports persistent joint pain despite well-controlled inflammation.…
Abstract Number: 1987 • ACR Convergence 2025
Evaluating User Engagement and Real-World Impact of a PMR-Specific Digital Symptom Assessment Tool: A 12-Month Analysis of PainSpot™
Shilpa Venkatachalam¹, Erik Stone², Ian Carroll³, angela Degrassi³, Shelley Fritz⁴ and David Curtis⁵, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Kalaheo, HI, ⁵Global Healthy Living Foundation, Meriden
Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory condition affecting individuals over 50, marked by bilateral shoulder and hip stiffness and pain. Its nonspecific symptoms…
Abstract Number: 1461 • ACR Convergence 2025
Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti-inflammatory treatment, substantially impacting patients' quality of life. Digital health applications (DiGAs) provide…
Abstract Number: 1238 • ACR Convergence 2025
Pain Is Associated with An Increased Risk of Frailty in Veterans with Rheumatoid Arthritis
Nadine El-ayache¹, Sayuli Bhide², Hannah Brubeck³, Punyasha Roul⁴, Bryant England⁵, Joshua Baker⁶, Grant Cannon⁷, Namrata Singh⁸, Gary Kunkel⁹, Ted Mikuls⁵, Patti Katz¹⁰, Dolores Shoback¹¹, Jose Garcia¹², Pradeep Suri¹³, Marianna Gasperi¹³, Ariela Orkaby¹⁴, Una Makris¹⁵ and Katherine Wysham¹⁶, ¹VA Puget Sound Health Care System & University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³VA Puget Sound Health Care System, Seattle, WA, ⁴UNMC, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Washington, Bellevue, WA, ⁹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹⁰UCSF, San Rafael, CA, ¹¹San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ¹²VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, ¹⁴VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, ¹⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ¹⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty, an increased vulnerability to stressors, is commonly associated with aging and functional decline. Pain, prevalent among older adults, contributes to frailty in the…
Abstract Number: 1149 • ACR Convergence 2025
Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
Aleksander Lenert¹, Robyn Domsic², Jenna Thomason³, Melanie smith⁴, Petar Lenert⁵, Yongdong (Dan) Zhao⁶, Jonathan Templin¹, Mary Vaughan-Sarrazin¹, Daniel Solomon⁷ and Polly Ferguson⁸, ¹University of Iowa, Iowa City, IA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Washington, Seattle, WA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵University of Iowa Hospitals and Clinics, Iowa City, IA, ⁶Seattle Children’s Research Institute, Redmond, WA, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁸University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Patient symptoms are important in the assessment of disease activity. The Patient Acceptable Symptom State (PASS) is defined as the minimum symptom score beyond…
Abstract Number: 0492 • ACR Convergence 2025
Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis
karun Shrestha¹, Pravakar Parajuli², Anil Regmi³, Prakriti Subedi⁴, Manoj Ghimire⁵, Sajana Poudel⁶, Mohammed Hasan⁷, Mahmoud Hashim⁸, Veera Durga Vaishnavi Kurra⁹ and ClementT Taoge¹⁰, ¹Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY ¹⁰⁴⁵⁷, USA, BRONX, NY, ²Patan Academy of Health Sciences-School of Medicine (PAHS-SOM), Lalitpur, Bagmati, Nepal, ³Parkview Health, Fort Wayne, IN, ⁴St. Barnabas Hospital, Bronx, NY, ⁵St Barnabas Hospital, BRONX, NY, ⁶Cook County Health, CHICAGO, NY, ⁷Parkview Medical Center, Pueblo, CO, ⁸SBH Health System, New Rochelle, NY, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Albert Einstein College of Medicine - Montefiore Medical Center, Bronx
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease of the joints with an estimated prevalence of 0.5% of people. Nearly 25% of RA patients…
Abstract Number: 0199 • ACR Convergence 2025
Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study
Abebawork Adem¹, Alfonso Sucerquia², Jose Forero³, Juan Alzate², Larry Moreland⁴, Gary Firestein⁵, Andres Cadena⁶ and Aileen Chang⁷, ¹George Washington University, Washington, DC, DC, ²The George Washington University, Arlington, ³The George Washington University, Arlington, VA, ⁴University of Colorado, Denver, CO, ⁵University of California, San Diego, San Diego, CA, ⁶Clinica de la Costa, Barranquilla, Colombia, ⁷The George Washington University, Washington
Background/Purpose: Chronic chikungunya arthritis (CCA) is a long-term sequela of chikungunya virus infection marked by persistent pain, disability, and reduced quality of life. While nociplastic,…
Abstract Number: 2320 • ACR Convergence 2025
Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors
Lourdes Perez Chada¹, Vivi Feather², Grace Carter², Helen Early³, Emily Tsai², Jing Cui⁴, Avery LaChance⁵, Rochelle Castillo⁶, Neda shahriari², Alexis Ogdie⁷, Monika Haack², Elizabeth Klerman², Michael Weinblatt⁸, Nancy Shadick⁹, Joseph Merola¹⁰ and Chinmayi Naik³, ¹Harvard Medical School, Wayland, MA, ²Mass General Brigham, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Jamaica Plain, MA, ⁶Brigham and Women's Hospital, Brookline, MA, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁸Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁹Brigham & Women's Hospital, Boston, MA, ¹⁰UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sleep disturbance is a common and burdensome symptom in psoriatic arthritis (PsA), but its clinical determinants remain poorly understood. Using data from the Cohort…
Abstract Number: 1965 • ACR Convergence 2025
Two-Year Outcomes of Microwave Ablation for Recurrent Monoarthritis with Synovial Hypertrophy Resistant to Medical Treatment: Expanded Cohort and Long-Term Follow-Up Results
Rabia Deniz¹, Tevfik Güzelbey², İlhan Nahit Mutlu², Kübra Kalkan³, Özgür Kılıçkesmez² and Cemal Bes⁴, ¹University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ²University of Health Sciences Başakşehir Çam and Sakura City Hospital, Department of Radiology, Istanbul, Turkey, ³University of Health Sciences Başakşehir Çam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, ⁴University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey
Background/Purpose: Recurrent monoarthritis (RM) is a significant therapeutic challenge in rheumatology, often persisting despite NSAIDs, corticosteroids (CS), DMARDs, and biologic therapies. Local interventions like intra-articular…
Abstract Number: 1435 • ACR Convergence 2025
Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Denis Poddubnyy¹, Victoria Navarro-Compan², Neil Basu³, Mohammad Naffaa⁴, Tianming Gao⁵, Christopher Saffore⁶, Jamie Urbanik⁷, Bhumik Parikh⁸, Peter Taylor⁹ and Philip J. Mease¹⁰, ¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel, ⁵AbbVie, North Chicago, IL, ⁶AbbVie Inc., waukegan, IL, ⁷AbbVie, Grayslake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹University of Oxford, Oxford, United Kingdom, ¹⁰Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated improvements in inflammation and nociceptive pain in late phase clinical trials of patients with axSpA.1,2,3 However,…
Abstract Number: 1237 • ACR Convergence 2025
Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
Michael Rosenbluth¹, Yifei Dai¹, Dianne Shumay¹ and Andrea Chadwick², ¹Swing Therapeutics, San Francisco, CA, ²University of Kansas School of Medicine, Kansas City, KS
Background/Purpose: Guidelines for fibromyalgia treatment recommend non-pharmacologic treatment, including cognitive behavioral therapy, alongside medications [1-3]. However, patient access to multi-modal treatment is frequently limited due…
Abstract Number: 1086 • ACR Convergence 2025
Leveraging Natural Language Processing to Uncover Real-World Trends in Cannabis Use from Clinic Notes in Electronic Health Records
Titilola Falasinnu¹, Nathan Le², Yiyu Wang², Aishwarya Alagappan², Michael Weisman³, Anushka Irani⁴, Yashaar Chaichian⁵ and Selen Bozkurt⁶, ¹Stanford School of Medicine, Palo Alto, CA, ²Stanford School of Medicine, Stanford, CA, ³Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁴Mayo Clinic, Jacksonville, FL, ⁵Stanford University, Stanford, CA, ⁶Emory University School of Medicine, Atlanta, GA
Background/Purpose: Pain management in autoimmune rheumatic diseases (ARDs) increasingly includes NSAIDs, physical therapy, and self-management. However, the role of cannabis in ARD symptom relief remains…
Abstract Number: 0470 • ACR Convergence 2025
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Peter Taylor¹, Yoshiya Tanaka², Louis Dron³, Katrien Van Beneden⁴, Gerd Burmester⁵ and Bruno Fautrel⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Cytel, Toronto, Canada, ⁴Alfasigma S.p.A., Bologna, Italy, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Janus kinase inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). Pain response trajectories were modeled…

« Previous Page
1
…
3
4
5
6
7
…
44
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].